Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Sanofi Warns on ’13 Profit as Second Quarter Earnings Slump

By Pharmaceutical Processing | August 1, 2013

PARIS (AP) — Competition from generic drugs continued to hammer French pharmaceutical group Sanofi in the second quarter, the company said Thursday, warning that its full-year earnings could be twice as bad as previous guidance.

The Paris-based drugmaker reported Thursday that net profit shrank 62 percent to 444 million euros ($592 million) in the April to June quarter, as the loss of patent on once-popular blood-thinner Plavix compounded further massive financial charges related to the company’s past mergers and acquisitions.

Sanofi warned that its preferred measure of profits — what it calls business EPS at constant exchange rates — will fall by 7 to 10 percent this year. Profit slumped 12.8 percent by that measure last year and until now the company had foreseen at most a 5 percent decline this year.

Profits by that measure collapsed a full 25 percent in the first half, but in a statement Thursday Sanofi said it “continues to expect to return to growth in the second half of 2013,” making up for some of the losses.

Besides losses stemming from generic competitors, Sanofi pointed to a steep drop in its own generics business during the second quarter. It blamed “significantly and inappropriately” excessive inventory levels in its Brazilian operations, leading to a 122 million euro drop in sales there.

Sanofi’s “growth platforms”, the core businesses such as diabetes treatments and vaccines that it counts on for nearly three-quarters of total sales, slipped 0.6 percent to 5.718 billion euros in the second quarter.

Sanofi shares dropped sharply on the weak earnings and by mid-morning were down 6.3 percent at 75.17 euro a share.

In China, where last month officials launched a probe looking into the cost of drugs made by 60 foreign and domestic suppliers, Sanofi said it is among the companies visited.

There was no indication of wrongdoing, but the probe could be a prelude to a cut in government-set caps on prices.

Sanofi said it is “not aware of the purpose of this visit” and said it would cooperate with authorities.

 

Related Articles Read More >

Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE